Anthony Boral

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.

A. Shaw, E. Felip, A. Santoro, 2012 .

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

Makoto Nishio, Haruyasu Murakami, Takashi Seto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

J. Engelman, A. Shaw, E. Felip, 2013 .

Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.

M. Fischer, B. Geoerger, C. Zwaan, 2015 .